The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,293,880 in first-year total cost, median $306,797.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-D (M1)]2
- Special Emphasis Panel[ZRG1 BBBT-F (10)]2
- Special Emphasis Panel[ZAG1 ZIJ-5 (M2)]1
- Special Emphasis Panel[ZAR1 KM (M1)]1
- Special Emphasis Panel[ZDK1 GRB-Q (M4)]1
Most frequent institutions
- AIRALUX MEDICAL, INC.1
- BOOKLILLICARES, LLC1
- CLAIRYON, INC.1
- ELECTRONIC BIOSCIENCES, INC.1
- ESK THERAPEUTICS, INC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | emuLAAte: atraumatic patient-specific stroke prevention technology1R43HL180201-01 | VERHEYEN, CONNOR | SPHERIC BIO INC, DE | $598,636 | ZRG1 |
| 2025 | A cell-permeable peptide therapeutic to reduce myocardial reperfusion injury1R43HL182534-01 | SHORES, LUCAS | LABORECOM THERAPEUTICS INC., IL | $457,232 | ZHL1 |
| 2025 | Automating Quality to Accelerate Transformational Improvements in Care (AQUATIC)1R44LM014847-01 | KOLASANI, HARI | CLAIRYON, INC., CA | $410,924 | ZRG1 |
| 2025 | SpinSeq1R43HG014419-01 | PETERSON, AMBERLYN MEGAN | ELECTRONIC BIOSCIENCES, INC., CA | $383,482 | ZRG1 |
| 2025 | Commercialization of a Biologic Eyedrop for Persistent Corneal Epithelial Defects1R43EY037619-01A1 | LAMPE, JANA B. | ESK THERAPEUTICS, INC, TX | $330,169 | ZEY1 |
| 2025 | Innovative glycan-specific reagents to accelerate the detection of disease biomarkers1R44GM159548-01 | BENDZUNAS, GEORGE NATHANIEL | LECTENZ BIO, INC., GA | $313,827 | ZRG1 |
| 2025 | Implementing a tech platform for training & consumer access to nanny agency sourced caregivers; a nascent elder companion care workforce1R43AG097252-01 | NADIMPALLI, SARAH BERGMAN | BOOKLILLICARES, LLC, RI | $306,872 | ZAG1 |
| 2025 | DIGITAL INCENTIVE SPIROMETRY EXERCISER TO IMPROVE PATIENT ADHERENCE AND CLINICAL WORKFLOWS1R43HL180242-01A1 | HSIEH, YI-AN | AIRALUX MEDICAL, INC., PA | $306,872 | ZHL1 |
| 2025 | Personalized postoperative management and physical therapy enabled by sensorized bone plates for traumatic fractures.1R43AR086046-01 | WILLIAMS, KYLIE E | PENDERIA TECHNOLOGIES, INC., OR | $306,722 | ZRG1 |
| 2025 | A rapid point-of-care test for therapeutic drug monitoring of tacrolimus1R43TR005794-01 | HEGGESTAD, JACOB | SIMPLUSDX, INC., NC | $306,299 | ZRG1 |
| 2025 | Reformulating NT-Z001 and its delivery route to treat rheumatoid arthritis1R43AR086088-01A1 | QI, YANMEI | NAVEGA THERAPEUTICS, INC., CA | $297,327 | ZAR1 |
| 2025 | Impedance-based bone health characterization for predictive osseointegration and patient-specific treatment1R43DE035036-01 | EVERITT, ALICIA | RYTEK MEDICAL, INC., NH | $296,171 | ZRG1 |
| 2025 | Manufacturing Clinical-Grade Cell Capsule of O2Line(TM) Implant System for T1D1R43DK143903-01 | KIM, BEUM JUN | PERSISTA BIO INC, NY | $287,250 | ZRG1 |
| 2025 | Development and Validation of Efficient Algorithms for Real-Time Glucose Monitoring on a Multi-Sensor Integrated Platform1R43DK143874-01 | HONARVAR NAZARI, NARGES | INTEGRATED MEDICAL SENSORS, CA | $284,999 | ZRG1 |
| 2025 | Oxygen reducing microcapsules for in vitro control of hypoxia1R44GM159549-01 | MOLLEY, THOMAS GREGORY | OXYLO, INC., CA | $229,072 | ZRG1 |
| 2025 | Phagineering the gut microbiome: Bacteriophages to reduce Desulfovibrio spp. and hydrogen sulfide in the intestine1R43DK145380-01 | BOECKMAN, JUSTIN XAVIER | INPHASOL INC., TX | $178,026 | ZDK1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.